Julie A Johnson

List of Publications by Year
in descending order

113 papers	6,473 citations	94433 37 h-index	74163 75 g-index
115 all docs	115 docs citations	115 times ranked	9144 citing authors

#	Article	IF	Citations
1	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics, 2018, 50, 524-537.	21.4	1,124
2	Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response. Annual Review of Genomics and Human Genetics, 2001, 2, 9-39.	6.2	365
3	Î²1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical Pharmacology and Therapeutics, 2003, 74, 44-52.	4.7	269
4	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260
5	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	2.9	213
6	The IGNITE network: a model for genomic medicine implementation and research. BMC Medical Genomics, 2015, 9, 1.	1.5	189
7	Ethnic Differences in Cardiovascular Drug Response. Circulation, 2008, 118, 1383-1393.	1.6	175
8	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
9	Clinical pharmacogenetics implementation: Approaches, successes, and challenges. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 56-67.	1.6	162
10	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	6.2	158
11	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clinical Pharmacology and Therapeutics, 2021, 109, 1417-1423.	4.7	157
12	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 447-460.	3.3	144
13	Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical Pharmacology and Therapeutics, 2004, 76, 536-544.	4.7	134
14	Pharmacogenetics of Î²-Blockers. Pharmacotherapy, 2007, 27, 874-887.	2.6	132
15	Warfarin pharmacogenetics. Trends in Cardiovascular Medicine, 2015, 25, 33-41.	4.9	128
16	Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. American Heart Journal, 2009, 157, 442-449.	2.7	119
17	Î²-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*. Clinical Pharmacology and Therapeutics, 2005, 77, 127-137.	4.7	116
18	Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. Hypertension, 2013, 62, 391-397.	2.7	96

#	Article	IF	Citations
19	CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genetics in Medicine, 2019, 21, 1842-1850.	2.4	96
20	Plasma Renin Activity Predicts Blood Pressure Responses to Â-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension. American Journal of Hypertension, 2010, 23, 1014-1022.	2.0	91
21	Pharmacogenetics: potential for individualized drug therapy through genetics. Trends in Genetics, 2003, 19, 660-666.	6.7	90
22	Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature Reviews Nephrology, 2016, 12, 110-122.	9.6	90
23	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
24	Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics, 2013, 14, 723-726.	1.3	76
25	Pharmacogenomics of Hypertension: A Genomeâ€Wide, Placeboâ€Controlled Crossâ€Over Study, Using Four Classes of Antihypertensive Drugs. Journal of the American Heart Association, 2015, 4, e001521.	3.7	74
26	Genetic variation at 16q24.2 is associated with small vessel stroke. Annals of Neurology, 2017, 81, 383-394.	5.3	73
27	Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharmaceutical Research, 2002, 19, 1779-1787.	3.5	67
28	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 2007, 17, 719-729.	1.5	65
29	Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics, 2017, 18, 421-426.	1.3	64
30	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
31	Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and Genomics, 2011, 21, 42-49.	1.5	52
32	Challenges and lessons learned from clinical pharmacogenetic implementation of multiple geneâ€“drug pairs across ambulatory care settings. Genetics in Medicine, 2019, 21, 2264-2274.	2.4	50
33	CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. Journal of the American Heart Association, 2015, 4, e001652.	3.7	44
34	Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course. American Journal of Pharmaceutical Education, 2016, 80, 122.	2.1	43
35	Advancing management of hypertension through pharmacogenomics. Annals of Medicine, 2012, 44, S17-S22.	3.8	41
36	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to Î²-Blockers in Hypertensive African Americans. Hypertension, 2016, 67, 556-563.	2.7	41

#	Article	IF	Citations
37	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine, 2018, 16, 92.	4.4	41
38	How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clinical Pharmacology and Therapeutics, 2021, 110, 677-687.	4.7	39
39	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. Journal of Hypertension, 2015, 33, 2278-2285.	0.5	38
40	Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. Stem Cells Translational Medicine, 2015, 4, 1380-1390.	3.3	36
41	Genome-wide study of resistant hypertension identified from electronic health records. PLoS ONE, 2017, 12, e0171745.	2.5	36
42	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension, 2017, 69, 51-59.	2.7	34
43	Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Molecular Biotechnology, 2016, 58, 179-187.	2.4	33
44	Largeâ€Scale Geneâ€Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	3.7	32
45	Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clinical and Translational Science, 2018, 11, 175-181.	3.1	32
46	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	2.4	32
47	A Summer Research Training Program to Foster PharmD Students' Interest in Research. American Journal of Pharmaceutical Education, 2008, 72, 23.	2.1	31
48	A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication. PLoS ONE, 2015, 10, e0113808.	2.5	30
49	Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. Journal of Clinical Medicine, 2020, 9, 2274.	2.4	29
50	Qualitative study of system-level factors related to genomic implementation. Genetics in Medicine, 2019, 21, 1534-1540.	2.4	26
51	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	4.7	25
52	Pharmacogenetic Associations of Î²1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke, 2017, 48, 1337-1343.	2.0	24
53	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. Clinical Pharmacology and Therapeutics, 2020, 108, 557-565.	4.7	24
54	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23

#	Article	IF	Citations
55	Factors Influencing Blood Pressure Response to Trandolapril Add-On Therapy in Patients Taking Verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). American Journal of Cardiology, 2007, 99, 1549-1554.	1.6	22
56	Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of Translational Medicine, 2012, 10, 47.	4.4	22
57	Novel Implementation of Genotypeâ€Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. Clinical and Translational Science, 2019, 12, 172-179.	3.1	22
58	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	2.7	21
59	Pharmacogenetic factors affecting Î²-blocker metabolism and response. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 953-964.	3.3	20
60	Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. Current Opinion in Pharmacology, 2016, 27, 31-37.	3.5	19
61	Genomeâ€Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to Î²â€Blockers. Journal of the American Heart Association, 2018, 7, .	3.7	18
62	A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. Clinical Pharmacology and Therapeutics, 2020, 108, 116-125.	4.7	17
63	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	2.4	17
64	A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genetics in Medicine, 2021, 23, 621-628.	2.4	17
65	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	2.0	16
66	Academia at the crossroads: education and training in pharmacogenomics. Personalized Medicine, 2012, 9, 497-506.	1.5	15
67	Genetic Variants Associated With Uncontrolled Blood Pressure onÂThiazide Diuretic/Î²â€Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)Âand INVEST (International Verapamilâ€SR Trandolapril Study) Trials. Journal of the American Heart Association, 2017, 6, .	3.7	15
68	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics, 2016, 12, 1.	3.0	14
69	Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. Hypertension, 2019, 74, 614-622.	2.7	14
70	Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. Journal of Clinical Hypertension, 2019, 21, 91-101.	2.0	14
71	Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. Journal of the American Heart Association, 2018, 7, .	3.7	13
72	Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. European Journal of Pharmaceutical Sciences, 2019, 131, 93-98.	4.0	13

#	Article	IF	Citations
73	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotypeâ€Derived Activity Scores. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 678-685.	2.5	13
74	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. Journal of Personalized Medicine, 2021, 11, 647.	2.5	13
75	Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. American Journal of Hypertension, 2012, 25, 359-365.	2.0	12
76	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, dju437-dju437.	6.3	12
77	Determination of Human ??2-Adrenoceptor Haplotypes by Denaturation Selective Amplification and Subtractive Genotyping. Molecular Diagnosis and Therapy, 2001, 1, 315-322.	3.3	11
78	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. Journal of Clinical Hypertension, 2017, 19, 1301-1308.	2.0	11
79	Baseline predictors of central aortic blood pressure: A PEAR substudy. Journal of the American Society of Hypertension, 2014, 8, 152-158.	2.3	10
80	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics, 2016, 12, 1.	3.0	10
81	Whole Transcriptome Profiling: An RNAâ€Seq Primer and Implications for Pharmacogenomics Research. Clinical and Translational Science, 2018, 11, 153-161.	3.1	10
82	Clinical Pharmacology Education â€“ The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 37-39.	4.7	10
83	Pharmacists should jump onto the clinical pharmacogenetics train. American Journal of Health-System Pharmacy, 2016, 73, 2013-2016.	1.0	9
84	Î²₂â€Adrenergic Receptor Gene Affects the Heart Rate Response of Î²â€Blockers: Evidence From 3 Clinical Studies. Journal of Clinical Pharmacology, 2019, 59, 1462-1470.	2.0	9
85	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. American Journal of Hypertension, 2019, 32, 668-675.	2.0	9
86	Essential Characteristics of Pharmacogenomics Study Publications. Clinical Pharmacology and Therapeutics, 2019, 105, 86-91.	4.7	9
87	Clinical Utility of Pharmacogene Panelâ€Based Testing in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Translational Science, 2020, 13, 473-481.	3.1	9
88	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	2.4	9
89	Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. American Journal of Hypertension, 2016, 29, 1186-1194.	2.0	8
90	Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB Journal, 2020, 34, 7941-7957.	0.5	8

#	Article	IF	Citations
91	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS ONE, 2019, 14, e0221957.	2.5	7
92	Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease. Pharmacogenomics Journal, 2021, 21, 657-663.	2.0	7
93	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. Metabolites, 2021, 11, 645.	2.9	7
94	Impact of the ABCDâ€CGENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multiâ€Site, Realâ€World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	4.7	7
95	Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenetics and Genomics, 2018, 28, 251-255.	1.5	6
96	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Medical Genomics, 2018, 11, 55.	1.5	6
97	The Patientâ€Centered Future of Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2020, 107, 72-75.	4.7	6
98	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	4.7	6
99	Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Scientific Reports, 2019, 9, 17323.	3.3	5
100	Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. American Journal of Hypertension, 2020, 33, 316-324.	2.0	5
101	Use of pharmacogenetics in clinical medicine: hype or hope?. Personalized Medicine, 2005, 2, 279-282.	1.5	4
102	Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension. Frontiers in Genetics, 2022, 13, 836636.	2.3	4
103	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Research and Clinical Practice, 2014, 104, 363-369.	2.8	3
104	A case for genotype-guided pain management. Pharmacogenomics, 2019, 20, 705-708.	1.3	3
105	Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. American Journal of Medicine, 2021, 134, 918-925.e2.	1.5	3
106	Î²1â€receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. Clinical and Translational Science, 2022, 15, 619-625.	3.1	3
107	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 343-351.	1.0	1
108	A Randomized, Crossâ€over Trial of Metoprolol Succinate Formulations to Evaluate <scp>PK</scp> and <scp>PD</scp> Endpoints for Therapeutic Equivalence. Clinical and Translational Science, 2022, , .	3.1	1

#	Article	IF	Citations
109	Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. Genes, 2022, 13, 1260.	2.4	1
110	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. American Journal of Hypertension, 2020, 33, e2-e2.	2.0	0
111	What will be your legacy in pharmacy? How will you be a Paul Parker?. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 6-7.	1.0	0
112	Tribute to Professor Hartmut Derendorf â€•1953 to 2020: Driving force in Clinical Pharmacology and Mentor Extraordinaire. Clinical Pharmacology and Therapeutics, 2021, 109, 805-809.	4.7	0
113	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0